For instance, hypomethylating agents such as azacitidine or decitabine, when paired with HDAC inhibitors, not only enhance global chromatin accessibility but also amplify pro-apoptotic signaling cascades, leading to improved therapeutic responses in otherwise refractory AML models. Here, HDAC9 is linked to acute myeloid leukemia.